Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05430958
Other study ID # COVID19-131
Secondary ID
Status Withdrawn
Phase Phase 1
First received
Last updated
Start date October 2022
Est. completion date March 2024

Study information

Verified date November 2022
Source Inovio Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open label, phase 1 clinical trial of an intra-dermal booster dose of INO-4800 alone or in combination with INO-9112 followed by electroporation (EP) among healthy adults at least 18 years of age, who previously completed their primary immunization series with mRNA vaccines against SARS-CoV-2 within 6-12 months prior to the booster dose.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date March 2024
Est. primary completion date March 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Healthy men and non-pregnant women at least 18 years of age; - Able and willing to comply with all study procedures; - Screening laboratory results within normal limits or deemed not clinically significant by the Investigator; - Received full primary series doses of an approved or authorized mRNA vaccine at least 6 months but no more than 12 months prior to INO-4800 booster dose. - Must meet one of the following criteria with respect to reproductive capacity: - Women who are post-menopausal as defined by reported spontaneous amenorrhea for = 12 months; - Surgically sterile (i.e., vasectomy in males or tubal ligation, absence of ovaries and/or uterus in females). In the case of vasectomy, participants should wait six (6) months post-vasectomy prior to enrollment; - Use of medically effective contraception with a failure rate of < 1% per year when used consistently and correctly from screening until Day 28 post booster dose. Exclusion Criteria: - Acute febrile illness with temperature >100.4°F (38.0°C) or acute onset of upper or lower respiratory tract symptoms (e.g., cough, shortness of breath, sore throat) within the prior 72 hours; - Positive SARs-CoV-2 PCR test, if results are available prior to dosing; - Pregnant or breastfeeding, or intending to become pregnant or intending to father children within the projected duration of the study starting from the Screening visit until Day 28 post booster dose; - Positive pregnancy test during screening or immediately prior to booster dose; - Positive HIV rapid test, Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody at Screening; - Is currently participating or has participated in a study with an IP within 30 days preceding Day 0 (documented receipt of placebo in a previous study would be permissible for study eligibility); - Currently participating in another study with an investigational product during the conduct of this study; - Previous or planned receipt of any COVID-19 booster vaccine during the trial period - Medical conditions as follows: - Respiratory diseases - History of hypersensitivity or severe allergic reaction - Uncontrolled hypertension - Uncontrolled diabetes mellitus - Malignancy within the past 2 years, with the exception of superficial skin - History of cardiovascular disease - History of myocarditis or pericarditis - History of seizures within the past 2 years - Underlying immunosuppressive illness - Lack of acceptable sites for ID injection and EP - Blood donation or transfusion within 1 month prior to Day 0; - Reported alcohol or substance abuse/dependence or illicit drug use within the past year; - Any non-study vaccine (e.g., influenza vaccine) within 2 weeks prior to the dose of IP.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
INO-4800
INO-4800 will be given at 0.8 or 1.6 mg for at least 6 months but no more than 12 months following the completion of a primary vaccination.
INO-9112
INO-9112 will be given in at various doses (dose of 0, 0.05, 0.10, 0.20 or 0.40 mg) in combination with INO-4800.
Device:
CELLECTRA® 2000
Electroporation (EP) using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Inovio Pharmaceuticals

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants with Solicited Local and Systemic Adverse Events (AEs) Baseline up to Day 7
Primary Percentage of Participants with Adverse Events (AEs) Baseline up to Day 28
Primary Percentage of Participants with Serious Adverse Events (SAEs) Baseline up to week 52
Primary Percentage of Participants with Adverse Events of Special Interest (AESIs) Baseline up to week 52
Primary Percentage of Participants with Incidence of medically attended AEs (MAAEs) Baseline up to week 52
Primary Percentage of Participants with Change in SARS-CoV-2 pseudovirus neutralizing titers Baseline up to day 28
Secondary Number of Participants with a Change in SARS-CoV-2 pseudovirus neutralizing titers Baseline, Day 7, 14, 84, 180, 224, 280 and 365 post-booster
Secondary Number of Participants with SARS-CoV-2 pseudovirus neutralizing titers Days 7, 14, 28, 84, 180, 224, 280 and 365 post-booster
Secondary Number of Participants with ARS-CoV-2 Spike binding IgG and change in SARS-CoV-2 Spike binding IgG Days 7, 14, 28, 84, 180 and 365 post-booster
Secondary Number of Participants with SARS-CoV-2 cellular immune response as measured by IFN-gamma ELISpot Day 14 post-booster
See also
  Status Clinical Trial Phase
Completed NCT04369456 - Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients N/A
Completed NCT04527471 - Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19 Phase 2
Recruiting NCT04410510 - P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 Phase 2/Phase 3
Withdrawn NCT04383899 - Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019
Completed NCT04542915 - COVID-19-Related Health and Practices Among Dental Hygienists
Not yet recruiting NCT04400019 - Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM) Phase 2/Phase 3
Suspended NCT04385771 - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation N/A
Terminated NCT04954014 - Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients Phase 2
Completed NCT04532632 - Taste and Smell Impairment in Critically Ill COVID-19 Patients
Terminated NCT04530448 - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization Phase 4
Completed NCT04413435 - Clinical Characteristics of Critically Ill Patients With COVID-19
Terminated NCT05593770 - International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response Phase 2/Phase 3
Completed NCT04510493 - Canakinumab in Patients With COVID-19 and Type 2 Diabetes Phase 3
Active, not recruiting NCT04587219 - The Study of "Gam-COVID-Vac" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older Phase 2
Completed NCT04596579 - SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida
Completed NCT04405934 - COG-UK Project Hospital-Onset COVID-19 Infections Study N/A
Enrolling by invitation NCT04484025 - SPI-1005 Treatment in Moderate COVID-19 Patients Phase 2
Terminated NCT04442230 - NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19) Phase 2
Terminated NCT04642638 - Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure Phase 2/Phase 3
Active, not recruiting NCT04527432 - COVID-19 Health Professional Impact Study N/A